New role for protein molecule that inhibits response of immune-system cells

Nov 09, 2010 By Jacquie Posey

Researchers at the University of Pennsylvania have identified a new role for a protein molecule that inhibits the response of immune-system cells to inflammatory signals associated with many human diseases.

An international group of scientists, with lead researchers in Penn’s School of Veterinary Medicine and School of Medicine, has shown the unique ability of a protein subunit called IL-27p28 to bind with a key cell receptor (gp130), effectively preventing it from transmitting signals necessary for triggering an immune response. Regulating the production of the molecule could lead to new, targeted interventions for cancer, asthma, lupus, multiple sclerosis, arthritis and other diseases.

“Lots of pharmaceutical companies are focused on possible targets upstream or downstream of this key receptor,” said Christopher Hunter, professor and chair of pathobiology in Penn Vet. “Here, we’ve discovered a natural molecule that limits signaling through that receptor. There’s already genetic data out there saying this protein is important in human medicine. We agree with that, but maybe it works a different way than we thought before. Then, having this information means that this natural molecule provides a new way to manage different types of inflammatory diseases.”

Cytokines are important molecules that can promote or limit inflammation and are key contributors to the development of cancer and autoimmune diseases such as lupus, asthma, arthritis, multiple sclerosis, inflammatory bowel disease and Crohn’s disease. Previous research has sought to better understand how cytokines like IL-27 interact with their receptor complexes to develop new approaches for managing inflammation.

The Penn findings were surprising to the researchers because they showed that, alone. the p28 component of IL-27 was able to inhibit a receptor used by many immune cells, and the findings suggest that it may be useful therapeutically. These find ings highlight the combinatorial biology of this family of cytokines and raise questions about whether other subunits in this family have other unappreciated biological activities. Additional studies are needed to address the potential targets of IL-27p28 and whether IL-27p28 can be used as a therapeutic agent for the treatment of inflammatory conditions and malignancies that work through the gp130 receptor.

Explore further: The impact of bacteria in our guts

More information: The findings appear in this week’s Nature Immunology.

Related Stories

Protein's new role discovered in autoimmune disease

Jan 02, 2008

Investigators at the University of Alabama at Birmingham (UAB) have identified the previously unknown role of a chemical 'messenger' leading to autoimmune disorders like rheumatoid arthritis and lupus.

2 immune-system proteins linked to colitis-associated cancer

Feb 02, 2009

Recent research from the laboratory of Michael Karin, PhD, at the University of California, San Diego School of Medicine - the first researcher to demonstrate a molecular link between inflammation and cancer - has identified ...

Recommended for you

The impact of bacteria in our guts

Aug 22, 2014

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

Aug 22, 2014

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

Aug 22, 2014

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0